Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

  • STATUS
    Recruiting
  • End date
    Nov 17, 2022
  • participants needed
    416
  • sponsor
    Sunshine Lake Pharma Co., Ltd.
Updated on 17 July 2021
carcinoma
squamous cell carcinoma
potassium
EGFR
irinotecan
esophagus cancer
recurrent esophageal cancer

Summary

This is a randomized, controlled, multi-center, open trial, unresectable locally advanced or metastatic esophageal squamous cell carcinoma patients that failed at least second-line treatment and overexpressed EGFR were enrolled and randomly assigned to the experimental group and control group at a 1: 1 ratio.,who received Larotinib and the chemotherapy regimen chosen by the investigator (Irinotecan Hydrochloride Injection or Tegafur Gimeracil Oteracil Potassium Capsule),respecitively.

Subjects are administered until disease progression assessed by the RECIST V1.1 standard (unless the investigator evaluates that the subject continues to have clinical benefit from continuing treatment, the subject may be allowed to continue treatment), and begins to receive new anti-tumor treatment, unacceptable toxicity, withdrawal of informed consent, or other conditions that meet the criteria for terminating trial treatment / withdrawal from the trial.

The research phase of this study is divided into pre-screening period (~ D-28), screening period (D-28 ~ D-1), treatment period, treatment end visit ( 7 days after the last dose), safety follow-up ( Until 28 7 days after the last dose) and survival follow-up.

Description

The experimental group and the control group were administered until the disease progression assessed by the RECIST V1.1 standard (unless The investigator evaluates that the subject continues to have clinical benefits, and the subject can be allowed to continue receiving treatment), start new anti-tumor therapy, unacceptable toxicity, withdraw informed consent, ect.

The research phase of this study is divided into screening period, treatment period, treatment end visit, safety follow-up and survival follow-up.

Subjects who have finished the screening examination and evaluation after the screening period enter the treatment period, and evaluate the efficacy. Subjects who have finished the treatment need to continue to undergo safety follow-up ; For subjects who have finished the trial treatment due to toxic reactions or other reasons, and have not observed the progression, they still need to carry out imaging evaluation according to the original frequency until the occurrence of tumor progression judged by RECIST V1.1 standard, start of new anti-tumor therapy, withdrawal of informed consent, loss of follow-up, death, or end of study, whichever occurs first; all subjects receive survival follow-up until death,lost of ,the follow-up or the study endedwhichever occurred first.

PK studies: Pharmacokinetic (PK) studies are conducted only in centers with appropriate conditions. Only some subjects in the experiemtal group are required to undergo a PK study. Participate in intensive PK blood collection (8-12 cases), and participate in sparse PK blood collection (150 cases). Subjects participating in intensive PK blood collection do not participate in sparse PK blood collection.

Biomarker research: Detect EGFR overexpression and amplification research on tumor tissue samples for all subjects and explore the relationship between its efficacy and changes in EGFR overexpression and amplification status before and after treatment.

Details
Condition cancer of the esophagus, oesophageal carcinoma, Head and Neck Cancer, Esophageal Cancer, Esophageal Diseases, esophagus cancer, head and neck cancer, Esophageal Carcinoma, Esophageal Disorders, oesophageal cancer
Treatment Lerotinib, Irinotecan/Tegafur
Clinical Study IdentifierNCT04415853
SponsorSunshine Lake Pharma Co., Ltd.
Last Modified on17 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age:18-75 years, male or female
Histologically or cytologically confirmed squamous cell carcinoma of the esophagus or advanced/metastatic disease
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy of greater than 3 months
Documented objective radiographic or clinical disease progression on two previous lines of standard therapy
Can provide archival tumor tissue sample for biomarker analysis (such as EGFR overexpression/expansion status), biopsies are required if tissue samples cannot be provided
Confirmed by the central laboratory as EGFR high expression
Evaluable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
Ability to swallow drugs
Adequate organ function
Voluntarily join the study and sign informed consent ad has good compliance

Exclusion Criteria

Prior therapies with EGFR targeted drugs including EGFR antibodies
Previously treated with Irinotecan and Tegafur
Anthracycline, nitrosourea, and mitomycin within 6 weeks; traditional Chinese medicine for anti-tumor within 2 weeks;immune anti-tumor therapy. within 8 weeks;other anti-tumor therapies within 4 weeks before randomization
Not recovered from adverse events due to a previously administered agent
Have undergone major surgery within 4 weeks prior to randomization (not including diagnostic surgery) or expect major surgery during the study period
Previously or currently participating in other clinical trials within 4 weeks before randomization (subjects who have entered the follow-up period are calculated based on the last use of experimental drugs or devices)
Received a live vaccine within 28 days before randomization or plan to receive live vaccine after enrollment
Received a strong inducer or inhibitor of CYP3A4 enzyme within 1 week or received Solivudine or its structurally similar drugs within 56 days prior to randomization
Simultaneously receiving any other anti-tumor treatment
Has a known additional malignancy previously within the last 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin or any other tumor that has been cured
Central nervous system metastasis or uncontrolled central nervous system metastasis currently in need of treatment; or confirmed central nervous system metastasis, but not stable for more than 4 weeks after anti-tumor therapy; spinal cord compression, cancerous meningitis, or meningitis
Clinically obvious gastrointestinal abnormalities, which may affect the intake, transport or absorption of drugs
Having active gastrointestinal ulcer, active gastrointestinal bleeding, and perforation
Risk of major bleeding or esophageal fistula
Previous or present with interstitial lung disease or immunotherapy-associated pneumonia; currently suffering from drug-induced pneumonia, radiation pneumonitis requiring steroid therapy, or clinically symptomatic active pneumonia, or other moderate to severe lungs that seriously affect lung function disease
Active infection during the screening period (including but not limited to infection requiring intravenous drip therapy), or unexplained fever (> 38.5C)within 2 weeks prior to randomization
Has congenital or acquired immune deficiency (such as HIV infection)
Known active Hepatitis B or C
Has any of the following diseases within the first 12 months of randomization: myocardial infarction, coronary artery bypass grafting or peripheral artery bypass graft surgery, heart failure (NYHA III to IV), etc and unstable angina with 6 months
Has thrombosis or embolism occurred within the first 12 months of randomization, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis, pulmonary embolism with heparin or other similar drugs
QTc interval (QTcF) corrected by Fridericia method> 470 ms; history of congenital long QT interval syndrome; any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation) Or torsion-type ventricular tachycardia); left ventricular ejection fraction (LVEF) <50%
Allergies or contraindications to Z650 excipients (mannitol, sodium carboxymethyl starch, micronized silica gel, magnesium stearate, silicified microcrystalline cellulose), or to Irinotecan or Tegafur or its formulation ingredients
Has uncontrolled pleural effusion, pericardial effusion, pelvic effusion, or ascites requiring repeated drainage
Has a history of organ transplantation or a history of allogeneic bone marrow transplantation
Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 6 months after the last dose of study medication
Has other serious acute or chronic diseases and are not suitable for participating in clinical trials judged by investigators
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note